Biogen (NASDAQ:BIIB) reported Q2 non-GAAP earnings of $4.02 per diluted share, down from $5.25 a year earlier.
Analysts polled by Capital IQ expected $3.76.
Total revenue for the quarter ended June 30 was $2.46 billion, down from $2.59 billion a year earlier.
Analysts surveyed by Capital IQ expected $2.36 billion.
Biogen said it continues to expect full-year 2023 adjusted EPS of $15 to $16. Analysts polled by Capital IQ are expecting adjusted EPS of $15.43. Revenue for the year is expected to decline by mid-single-digit percentage from a year earlier.